Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Data ReadoutpositiveSER-155Positive

AI Analysis

Summary

Seres Therapeutics announced early clinical data demonstrating potential for SER-155 in treating immune checkpoint inhibitor-related enterocolitis (irEC), an adverse reaction that causes many cancer patients to discontinue treatment.

Clinical Trial Data

Outcome Details

Early clinical data showing potential for SER-155 in treating immune checkpoint inhibitor-related enterocolitis

Importance:6/10

Sentiment:

0.65

immuno-oncologyadverse_event_treatmentclinical_datamicrobiome

Related Companies

$MCRB

Read the original article

Published by yahoo_finance on July 8, 2026 11:00 AM

Read Original